

January 23, 2020

To: All Concerned Parties

Company Name: Solasia Pharma K.K.  
Representative: Yoshihiro Arai, President & CEO  
(Code number: 4597, TSE Mothers Section)  
Contact: Toshio Miyashita, CFO, Director  
Tel: 81-3-5843-8049

## PledPharma AB Announces Update on SP-04 (PledOx®) Clinical Study Information

PledPharma AB, Solasia's partner announced today regarding update on SP-04 (PledOx®) phase III clinical study. For more information, please refer to following URL link to PledPharma AB website.

[https://www.pledpharma.com/mfn\\_news/pledpharma-provides-update-on-the-clinical-polar-program-clinical-hold-in-the-us/](https://www.pledpharma.com/mfn_news/pledpharma-provides-update-on-the-clinical-polar-program-clinical-hold-in-the-us/)

###